P02.59. Complexity of disease and population heterogeneity require a rethinking of clinical trial design
Saved in:
Main Authors: | Amri H (Author), Haramati A (Author), Abu-Asab M (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2012-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Endometriosis Gene Expression Heterogeneity and Biosignature: A Phylogenetic Analysis
by: Mones Abu-Asab, et al.
Published: (2011) -
Psoriatic arthritis. When the heterogeneity requires normality
by: R. Ramonda, et al.
Published: (2012) -
P59 Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade
by: N. Scott, et al.
Published: (2017) -
Geriatric dentistry: Is rethinking still required to begin undergraduate education?
by: Talwar Manjit, et al.
Published: (2008) -
Rethinking bioequivalence and equivalence requirements of orally inhaled drug products
by: Dina Al-Numani, et al.
Published: (2015)